for providing a license to GastroPlus under the SLP University+ program ( Ethics declarations Competing interests The authors declare no competing interests
This narrative has real clinical consequences
Until human clinical trials validate BPC157s safety and effectiveness, and until regulatory bodies approve pharmaceutical-grade versions, it remains a biologically active but legally and clinically dicey regarding human injection
Here is a quick summary: Nausea: ~8 days median
Heres what the three patients from the small case study report experienced: Case 1: A 46-year-old woman on semaglutide developed dry mouth and coated tongue
Bukov A, Hochvaldov L, Veeov R, Malina T, Petr M, Kalk J et al (2025) Selenium nanoparticles: influence of reducing agents on particle stability and antibacterial activity at biogenic concentrations